Clinical Trial Update: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial [Phase 4]

View source ↗

Summary

Pilot Phase 4 trial update for alirocumab (Alirocumab) targeting stopping progression of atherosclerosis in saphenous vein grafts; the study status is terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Saphenous Vein Graft Atherosclerosis

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Minneapolis Heart Institute Foundation | Conditions: Saphenous Vein Graft Atherosclerosis | Phase 4 | Status: TERMINATED